CTXR
NASD Citius Pharmaceuticals Inc$0.4900 ↑ +0.0093 (+1.93%) Trading Up from the previous close of $0.4807, $0.0360 below the day’s high of $0.5260
- YTD change
- -36.94%
- vs 20-day SMA
- -13.64%
- vs 200-day SMA
- -29.90%
Price ranges
Price & Performance
-0.34 (-39.53%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 99.9% away from all-time highs of $371.2500
- CTXR is down 37% since the beginning of the year
- CTXR is down 63% over the past 12 months
- CTXR is down 17% over the past 1 month
- 21% of all CTXR investors are betting against CTXR
CTXR reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -60.9%.
- Previous minute
- +$0.0000
- Last hour
- +$0.0000
- Last 5 days
- -10.75%
- vs 8-day SMA
- -10.40%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. The company was founded by Ralph Montrone, Leonard Mazur, Myron Holubiak on January 23, 2007 and is headquartered in Cranford, NJ.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
